

ASX/Media Release
17 February 2011

PRIMA BIOMED APPOINTS NEW CFO

Australian healthcare company Prima BioMed Ltd (ASX: PRR) (Prima) is pleased to announce the appointment of Mr Ian Bangs as the Company's new Chief Financial Officer.

Mr Bangs' appointment is effective from today, and with the continued strong growth in Prima's business, he will play a key role in the Company's corporate management team.

He has a strong depth of experience and expertise in the financial management of publicly listed companies, with more than 25 years experience in senior finance positions with companies across a diverse range of industries.

Mr Bangs has previously held the roles of Chief Financial Officer and Company Secretary for a number of ASX-listed companies, including property and funds management group LandMark White Limited (ASX: LMW) and, prior to that, IFC Capital Limited (ASX: IFC) for 6.5 years.

He was also the CFO of the Four Seasons Hotel (formerly the Regent Hotel) in Sydney for a period of 10 years.

Mr Bangs has specific expertise in the day to day financial and administrative operations of companies, together with their statutory reporting and compliance obligations.

Commenting on the appointment Prima BioMed CEO Martin Rogers said: "The Company prides itself on the calibre of people it attracts. We have assembled a world-class clinical team and corporate management team, and are delighted to welcome Ian Bangs to the team. His corporate financial management skills will be invaluable to the Company as we continue to enjoy significant growth."

He has a Bachelor of Commerce degree and is a Fellow CPA.

ENDS

For further information please contact:

Mr Martin Rogers
Chief Executive Officer
Prima BioMed
Ph: +61 (0) 428 268 357
E: martin.rogers@primabiomed.com.au
W: www.primabiomed.com.au

Mr James Moses
Investor and Media Relations
Mandate Corporate
Ph: +61 (0) 420 991 574
E: james@mandatecorporate.com.au

About CVac™ Ovarian Cancer Treatment

CVac™ is Prima BioMed's lead product. It is of key importance as there is a large un-met medical need for new treatments for ovarian cancer which has a very high morbidity rate. CVac™ is a maintenance therapy administered post-surgery and post-chemotherapy to delay relapse and control metastases.

There are currently no products available as maintenance based therapies for ovarian cancer and the global market for ovarian cancer therapeutics was valued at US\$2.1b in 2007 and is expected to total US\$3.6b by 2010.

Regulatory approval and commercialisation of CVac™ is the core focus for Prima.

About Prima BioMed

Prima BioMed is an ASX listed Australian health care company. The Company is focused on technologies in the fields of cancer immunotherapy and immunology.

Prima's lead product is the CVac™ ovarian cancer therapy treatment. It has completed two successful clinical trials and is progressing toward eventual commercialisation in the United States, Australia, Europe, and globally.

The Company's broader, long term goal is to develop commercial cancer treatment technologies and programs for global markets.

.